Walleye Capital LLC Has $2.09 Million Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Walleye Capital LLC reduced its stake in ANI Pharmaceuticals by 56.6%, selling 40,725 shares, leaving them with approximately 31,284 shares valued at $2,094,000.
• Several hedge funds have also increased their positions in ANI Pharmaceuticals, contributing to institutional ownership of 76.05% of the company's stock.
• Analyst ratings for ANI Pharmaceuticals have improved, with multiple firms upgrading the stock to a strong-buy rating and setting a consensus target price of $84.75.

Walleye Capital LLC trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 56.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,284 shares of the specialty pharmaceutical company's stock after selling 40,725 shares during the quarter. Walleye Capital LLC owned approximately 0.14% of ANI Pharmaceuticals worth $2,094,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ANIP. Penn Capital Management Company LLC acquired a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $448,000. Jump Financial LLC acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $1,555,000. Hotchkis & Wiley Capital Management LLC grew its stake in shares of ANI Pharmaceuticals by 89.9% in the first quarter. Hotchkis & Wiley Capital Management LLC now owns 108,600 shares of the specialty pharmaceutical company's stock valued at $7,271,000 after buying an additional 51,420 shares in the last quarter. Advantage Alpha Capital Partners LP grew its stake in shares of ANI Pharmaceuticals by 37,674.1% in the first quarter. Advantage Alpha Capital Partners LP now owns 10,199 shares of the specialty pharmaceutical company's stock valued at $683,000 after buying an additional 10,172 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at about $1,311,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Matthew J. Leonard sold 2,528 shares of the firm's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $90.62, for a total transaction of $229,087.36. Following the completion of the transaction, the director owned 6,864 shares in the company, valued at $622,015.68. This trade represents a 26.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Antonio R. Pera sold 5,421 shares of the firm's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total value of $486,426.33. Following the sale, the director directly owned 29,952 shares of the company's stock, valued at $2,687,592.96. This represents a 15.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 405,538 shares of company stock valued at $35,690,131. 12.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of recent research reports. Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. HC Wainwright reiterated a "buy" rating and issued a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Piper Sandler reissued an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Truist Financial increased their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a report on Monday, August 11th. Finally, Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $84.75.

ANI Pharmaceuticals Stock Up 0.3%

ANIP stock traded up $0.29 during mid-day trading on Wednesday, hitting $94.39. The stock had a trading volume of 61,389 shares, compared to its average volume of 372,272. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $95.60. The company has a fifty day moving average of $74.48 and a 200 day moving average of $67.55. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -122.41 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the company posted $1.02 EPS. The firm's revenue was up 53.2% on a year-over-year basis. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.